Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Miglyol 812 N

Phase 3Small molecule

MMedical University of Graz

Miglyol 812 N is one of 2 small molecule programs targeting Polymorphic Light Eruption. It is currently in Phase 3.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polymorphic Light EruptionActive, not recruiting

Polymorphic Light EruptionPhase 3

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Polymorphic Light Eruption

#DrugCompanyPhaseTrials

Scenesse

CClinuvel Pharmaceuticals Limited

Miglyol 812 N

MMedical University of Graz

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Polymorphic Light Eruption1 trial

Vitamin D Supplementation in Polymorphic Light Eruption

Terminated·MMedical University of Graz·Phase 3·NCT01595893·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Miglyol 812 N. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Miglyol 812 N compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Miglyol 812 N. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Graz company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMedical University of Graz

Related News